Aurobindo Pharma Ltd

- No specific mention of new fundraising through debt or equity was made in the provided Q&A or management commentary on page 17 or surrounding pages. - The company reported a Gross Debt of USD 644 million as of the quarter-end with a net cash position of USD 178 million including investments. - Cash flow generation was strong with a free cash flow of USD 29.5 million before investments for PLI and new markets. - Ongoing capital expenditure includes PLI Capex, forward derivative plants, and capacity debottlenecking, but no new fundraising rounds were indicated. - The focus remains on internal cash generation, operational efficiencies, and prioritizing commercialisation of new projects without external funds mentioned. - The board has approved exploring restructuring of the Eugia vertical but no clarity yet on capital restructuring or raising funds. In summary, no explicit plans for new debt or equity fundraising were disclosed for the near term.

- PLI (Production Linked Incentive) facilities and investments targeted to be completed before 1st April 2024. - Commercialization of new projects in China and India expected by Q1 FY25. - Ongoing investments in forward derivative plants linked to Pen G plant, approx. INR 150-200 crores for 2-3 plants. - China plant completed; exhibit batches filed; European inspection done; expected commercial start by April 2024. - Continuing Capex for debottlenecking and maintenance to increase manufacturing capacity and efficiency. - Internal Capex focus beyond PLI includes enhancing Pen G plant utilization. - Eugia vertical restructuring under consideration by the board. - No specific large Capex for biosimilars highlighted, but investments continue as pipeline progresses toward commercialization from FY25 onwards.

- Eugia's injectable business is growing around 10% in volume, currently positioned 6th in the US injectable segment, with an aim to grow US sales to $100 million+ and overall global Eugia to $500 million this year (page 17). - European business revenues are expected to maintain around EUR 200 million with seasonal fluctuations within ±5% (page 17). - European injectable business to increase share within Europe; focus on scaling injectable pipeline in ROW markets after restructuring (pages 12, 14). - US generics business sees stable pricing and volume-led growth with expectation to cross 18% EBITDA margin (pages 9-11). - Pipeline includes 20+ product launches annually with continuous portfolio expansion but no blockbusters expected (page 12). - Biosimilars business launching products starting FY25, aiming for 6-7 oncology and immunology products in regulated and ROW markets by 2028 (page 15). - Overall expectation of 5%-8% constant currency growth in key segments (page 13).

- The company expects EBITDA margin to cross 18% for the current fiscal year and potentially exceed 20% with the stabilization of manufacturing processes and commercialization of PLI and other projects. - Europe business is expected to grow 5-8% year-on-year in constant currency, driven by expanded product portfolio and improved margins through operating leverage. - Eugia injectable business targets $500+ million sales for the year, with around $100 million from Europe and $400 million from the US. - Injectable and specialty businesses expect stable pricing and general volume growth, with no significant dependence on one-off opportunities. - Biosimilars pipeline commercializations are expected to start from FY25, contributing to revenue growth in the medium term. - The company aims to maintain growth momentum driven by new product launches, expanded markets, and operational efficiency improvements.

The transcript does not explicitly mention the current or expected order book or pending orders for Aurobindo Pharma Limited. However, some relevant points indicating business outlook and growth prospects include: - The company has a broad and growing product portfolio with over 200 products under development or already filed. - Eugia vertical (injectable business) is expanding, with aspirations to reach $500 million in revenue this fiscal year. - Capacity expansions and commercializations underway in India, China, and Europe, with new projects targeted for FY25. - The company is enhancing manufacturing capacity, including Pen G and PLI projects. - Continued investments in ANDA filings and biosimilar pipeline commercializations are aimed at driving future growth. - Management focusing on co-marketing and possibly direct marketing for biosimilars in India. No specific order book figures or pending order quantities are disclosed in the transcript.